Teva settles OxyContin litigation with Purdue Pharma

By E. Janene Geiss

Philadelphia, Aug. 29 - Teva Pharmaceutical Industries Ltd. said Tuesday that it has signed an agreement with Purdue Pharma LP to settle patent infringement litigation pertaining to Teva's generic version of Purdue's OxyContin (oxycodone Hcl extended-release) tablets pending in the U.S. District Court for the Southern District of New York.

Under the settlement, Teva said it will cease selling its infringing oxycodone products at a future date and Purdue Pharma said it will not pursue damages against Teva for past infringement.

The settlement agreement is subject to certain contingencies, including review by United States antitrust agencies and the district court.

Other terms of the settlement are confidential, Teva said.

Purdue Pharma said it has filed infringement actions to protect its OxyContin patents against other companies.

On Feb.1, the U.S. Court of Appeals for the Federal Circuit ruled the Purdue patents to have been infringed by extended-release oxycodone products sold by Endo Pharmaceuticals Inc. of Chadds Ford, Pa.

Purdue is a Stamford, Conn., privately held pharmaceutical company.

Teva is a Petach Tikva, Israel, pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.